Rise of iPSCs as a cell source for adoptive immunotherapy |
| |
Authors: | Atsutaka Minagawa Shin Kaneko |
| |
Affiliation: | 1. Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center of iPS cell Research and Application (CiRA), Kyoto University, Kawaharacho 53, Shogoin, Sakyouku, Kyoto, 606-8507, Japan
|
| |
Abstract: | Adoptive T cell transfer is a potentially effective strategy for treating cancer and viral infections. However, previous studies of cancer immunotherapy have shown that T cells expanded in vitro fall into an exhausted state and, consequently, have limited therapeutic effect. One way to overcome this obstacle is to use induced pluripotent stem cells (iPSCs) as a cell source for making effector T cells. In recent years, there have been several reports on generating effector T cells suitable for adoptive immunotherapy. The reported findings suggest that using iPSC technology, it may be possible to stably derive large numbers of juvenile memory T cells targeted to cancers or viruses. In this review, we describe a strategy for applying iPSC technology to immunotherapy and the characteristics of T cells derived from iPSCs. We also discuss how these technologies can be applied clinically in the future. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|